| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Waldencast plc (NASDAQ:WALD), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration ("FDA") has approved Obagi® saypha® MagIQ™ injectable hyaluronic acid ("HA") gel, the first product in the Obagi® saypha® collection under the Obagi Medical brand. This approval marks Waldencast's entry into the U.S. HA dermal filler market through Obagi Medical and reinforces the Company's ambition to become a multi-product innovator in aesthetics, doubling Obagi Medical's total addressable market to approximately $4.2 billion by 2029.
Waldencast plans to launch Obagi® saypha® MagIQ™ in the U.S. market alongside other important skin care innovations in 2026. This launch will leverage Obagi Medical's established network of practices and aesthetic professionals, creating synergies with the brand's fast-growing skincare business and driving enhanced value for both providers and patients. Obagi Medical expects additional account expansion driven by the new Obagi Medical injectable offering.
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology that creates a stable 3D HA matrix designed to provide natural-looking results with category leading capabilities including high HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile. The commercial launch of this first injectable HA gel will be followed by additional products in the saypha® line, including Obagi® saypha® ChIQ™ pending FDA approval.
Posted In: WALD
